Breakthrough therapy designation (FDA)

An FDA designation that expedites review of drugs showing preliminary clinical evidence of substantial improvement over available therapy for serious conditions. Awarded to psilocybin by USONA and Compass Pathways; does not alter DEA Schedule I status but enables prioritised review of clinical trials.